ClinicalTrials.gg
CompletedNCT01335698PRINCE2Updated Nov 9, 2018Results posted

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients

A Phase 3 interventional study of Atazanavir Sulphate and Ritonavir in HIV, sponsored by Bristol-Myers Squibb. Completed at 32 sites in 11 countries. Open to participants aged 3 Months to 11 Years. Per ClinicalTrials.gov, last updated 2018-11-09.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
3 Months to 11 Years
Sex
All
01

Study summary

The purpose of this study is to describe the safety, efficacy, and pharmacokinetics of a regimen of atazanavir powder boosted with ritonavir and an optimized dual nucleoside reverse transcriptase inhibitor in pediatric patients aged ≥3 months to \<11 years.

02

Conditions studied

  • HIV

Keywords

  • Pediatric
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria:

  • Confirmed -1 infection diagnosed by protocol criteria
  • Screening HIV RNA level ≥1000 copies/mL
  • ≥3 months to \<11 years of age at time of first treatment
  • Antiretroviral-naive or -experienced
  • At screening, all participants must have genotypic sensitivity to atazanavir and at least 2 nucleoside reverse transcriptase inhibitors (NRTIs), which must be approved for pediatric use at the local country.
  • Antiretroviral-experienced patients must also have documented phenotypic sensitivity at screening to atazanavir (Fold Change in susceptibility \<2.2) and to at least 2 NRTIs that are approved in their country

Key Exclusion Criteria:

  • Experienced participants who received atazanavir or atazanavir/ritonavir at any time prior to study enrollment or who have a history of 2 or more protease inhibitor failures
  • Antiretroviral-naïve or -experienced HIV-1-infected patients with to study medications
  • Cardiac rhythm abnormalities
  • Need for tenofovir
  • Weight \<5 or ≥35kg
  • >Grade 2 abnormality in /alanine transaminase levels
  • Coinfection with either or C virus
  • Any active Centers for Disease Control and Prevention Category C clinical condition
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Stage 1: Atazanavir + Ritonavir

    Participants received atazanavir powder orally (dosed by weight: 5 to \<10 kg=150 mg, 5 to \<10 kg=200 mg, 10 to \<15 kg=200 mg, 15 to \<25 kg=250 mg, 25 to \<35 kg=300 mg) once daily for 24 to 48 weeks or a weight ≥35 kg. Participants also received ritonavir once daily for 24 to 48 weeks or weight ≥35 kg in the form of 80-mg/mL solution, orally (dosed by weight 5 to \<25 kg=80 mg, 25 to \<35 kg=100 mg); 100-mg capsule, orally (dosed by weight 25 to \<35 kg=100 mg); or 100-mg tablet, orally (dosed by weight 25 to \<35 kg=100 mg)

    Drug: Atazanavir Sulphate · Drug: Ritonavir

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Died and With Adverse Events (AEs) Leading to Discontinuation, Hyperbilirubinemia, Jaundice, First-degree Arterioventricular Block, Tachycardia, and Rash on ATV Powder

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.

    Time frame: Day one to week 300 (approximately 22-Jan-2018)

  2. Number of Participants Who Experienced a SAE on ATV Powder

    SAE= any of the the following: is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event (defined as a medical event(s) that may not be immediately life threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the subject or may require intervention \[eg, medical, surgical\] to prevent one of the other serious outcomes listed in the definition above.) Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization

    Time frame: Day one to week 300 (approximately 22-Jan-2018)

  3. Number of Participants With A Center of Disease Control and Prevention (CDC) Class C AIDS Event on ATV Powder

    The CDC disease staging system assesses the severity of HIV disease by CD4 cell counts and by the presence of specific HIV-related conditions. CD4 counts are classified as 1: ≥500 cells/µL, 2: 200-499 cells/µL, and 3: \<200 cells/µL. Children with HIV infection are also classified in each of several categories. Category N: Not symptomatic. Category A: Mildly symptomatic. Category B: Moderately symptomatic. Category C: Severely symptomatic.

    Time frame: Day one to week 300 (approximately 22-Jan-2018)

  4. Number of Participants With Laboratory Test Results Meeting the Criteria for Grade 3-4 Abnormality on ATV Powder

    Criteria of the Division of AIDS for grading the severity of adult and pediatric adverse events as follows: Grade (Gr) 1=mild; Gr 2=moderate; Gr 3=severe; Gr 4=potentially life-threatening. Neutrophils (absolute) (adult and infants \>7 days): Gr 1=1.000-1300/mm\^3; Gr 2=750-999 mm\^3; Gr 3=500-749 mm\^3; Gr 4= \<500 mm\^3. Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase: Gr 1=1.25-2.5\*upper limit of normal (ULN); Gr 2=2.6-5.0\*ULN; Gr 3=5.1-10.0\*ULN; Gr 4= \>10.0\*ULN. Bilirubin, total (adults and infants \>14 days): Gr 1=1.1-1.5\*ULN; Gr 2=1.6-2.5\*ULN; Gr 3=2.6-5.0\*ULN; Gr 4= \>5.0\*ULN. Lipase: Gr 1=1.1-1.5\*ULN; Gr 2=1.6-3.0\*ULN; Gr 3=3.1-5.0\*ULN; Gr 4= \>5.0\*ULN. Bicarbonate, serum low: Gr 1=16.0 mEq/L-\<lower limit of normal; Gr 2=11.0-15.9 mEq/L; Gr 3=8.0-10.9 mEq/L; Gr 4= \<8 mEq/L. By criteria of the World Health Organization: Amylase: Gr 1=1.0-1.39\*ULN; Gr 2=1.40-2.09\*ULN; Gr 3.=2.10-5.0\*ULN; Gr 4= \>5.0\*ULN.

    Time frame: Day one to week 300 (approximately 22-Jan-2018)

Secondary outcomes

  1. Number of Participants With HIV RNA <50 Copies/mL and <400 Copies/mL in the Week 24 Atazanavir Powder Cohort and the Eligible Week 48 Atazanavir Powder Cohort

    Virologic success includes patients with HIV RNA \<50 copies/mL. Two cohorts were assessed: The Atazanavir Powder Cohort=patients who received treatment and did not switch to capsule before analysis Week 24 or before their HIV RNA Week 24 assessment, and the Eligible Week 48 Atazanavir Powder Cohort=patients who initiated study treatment at least 48 weeks before last person last visit and did not switch to capsule before analysis Week 48 or before their HIV RNA Week 48 assessment.

    Time frame: Day 1 of treatment to weeks 24 and 48

  2. Mean Change From Baseline in HIV RNA on ATV Powder

    Human immunodeficiency virus ribonucleic acid (HIV RNA) change from baseline using observed values

    Time frame: Baseline to Weeks 24 and 48

  3. Mean Change From Baseline in CD4 Percent on ATV Powder

    Change in CD4 percent using observed values

    Time frame: Baseline to Weeks 24 and 48

  4. CD4 Cell Count Changes From Baseline on ATV Powder

    CD4 cell count change from baseline using observed values

    Time frame: Baseline to Weeks 24 and 48

  5. Number of Participants With Emergent Genotypic Substitutions on ATV Powder Through Week 48

    Newly emergent substitutions are on-treatment substitutions that were not detected at baseline.Viral rebound in the resistance analysis was defined as: Less than a 1 log10 drop from baseline in plasma HIV RNA level by Week 16, confirmed by a second plasma HIV RNA level redrawn within 2 and 4 weeks from original sample. Or, a plasma HIV RNA level \>200 c/mL after Week 24, confirmed by a second plasma HIV RNA level redrawn within 2 and 4 weeks from original sample. Or, repeated plasma HIV RNA level ≥50 c/mL after Week 48. Viral rebound was defined as a plasma HIV RNA level ≥400 c/mL at any time in a patient who had previously achieved a plasma HIV RNA level \<50 c/mL. Or, a plasma HIV RNA level ≥50 c/mL and \<1,000 c/mL followed by a return to virologic suppression was considered a viral blip and not a viral rebound. NRTI=nucleoside reverse transcriptase inhibitor

    Time frame: Baseline through Week 48

  6. Maximum Observed Plasma Concentration (Cmax)

    To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV Cmax

    Time frame: Baseline to Week 2

  7. Minimum Plasma Concentration (Cmin)

    To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV Cmin

    Time frame: Baseline to Week 2

  8. Area Under the Concentration-Time Curve [AUC(TAU)]

    To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV AUC

    Time frame: Baseline to Week 2

07

Results

Posted Feb 8, 2016

Participant flow

Treatment Stage 1
Participant flow — Treatment Stage 1
MilestoneAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Started231221358
Completed15416266
Not completed88592
Withdrew: Lack of efficacy31331
Withdrew: Adverse event12211
Withdrew: Withdrawal by subject12010
Withdrew: Lost to follow-up11000
Withdrew: Poor compliance/noncompliance01020
Withdrew: No longer meets study criteria11010
Withdrew: Other10010
Treatment Stage 2
Participant flow — Treatment Stage 2
MilestoneAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Started15416266
Completed4111185
Not completed113581
Withdrew: Lack of efficacy21310
Withdrew: Adverse event20030
Withdrew: Withdrawal by subject31100
Withdrew: Poor compliance/noncompliance10131
Withdrew: Lost to follow-up10000
Withdrew: Capsules received at state hospital10000
Withdrew: Subject no longer meets study criteria00010
Withdrew: Switched to another formulation11000

Outcome measures

PrimaryNumber of Participants Who Died and With Adverse Events (AEs) Leading to Discontinuation, Hyperbilirubinemia, Jaundice, First-degree Arterioventricular Block, Tachycardia, and Rash on ATV Powder

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.

Time frame:
Day one to week 300 (approximately 22-Jan-2018)
Reported as:
Number · Participants
Number of Participants Who Died and With Adverse Events (AEs) Leading to Discontinuation, Hyperbilirubinemia, Jaundice, First-degree Arterioventricular Block, Tachycardia, and Rash on ATV Powder
ParticipantsAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Deaths00000
AEs leading to discontinuation32221
Hyperbilirubinemia related adverse events20970
Jaundice00330
Atrioventricular block, first degree00010
Tachycardia00100
Rash30451
PrimaryNumber of Participants Who Experienced a SAE on ATV Powder

SAE= any of the the following: is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event (defined as a medical event(s) that may not be immediately life threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the subject or may require intervention \[eg, medical, surgical\] to prevent one of the other serious outcomes listed in the definition above.) Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization

Time frame:
Day one to week 300 (approximately 22-Jan-2018)
Reported as:
Number · participants
Number of Participants Who Experienced a SAE on ATV Powder
participantsAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Number of Participants Who Experienced a SAE on ATV Powder63880
PrimaryNumber of Participants With A Center of Disease Control and Prevention (CDC) Class C AIDS Event on ATV Powder

The CDC disease staging system assesses the severity of HIV disease by CD4 cell counts and by the presence of specific HIV-related conditions. CD4 counts are classified as 1: ≥500 cells/µL, 2: 200-499 cells/µL, and 3: \<200 cells/µL. Children with HIV infection are also classified in each of several categories. Category N: Not symptomatic. Category A: Mildly symptomatic. Category B: Moderately symptomatic. Category C: Severely symptomatic.

Time frame:
Day one to week 300 (approximately 22-Jan-2018)
Reported as:
Number · Participants
Number of Participants With A Center of Disease Control and Prevention (CDC) Class C AIDS Event on ATV Powder
ParticipantsAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Pulmonary tuberculosis20100
Lymph node tuberculosis00010
Tuberculosis00010
Oropharyngeal Candidiasis10000
PrimaryNumber of Participants With Laboratory Test Results Meeting the Criteria for Grade 3-4 Abnormality on ATV Powder

Criteria of the Division of AIDS for grading the severity of adult and pediatric adverse events as follows: Grade (Gr) 1=mild; Gr 2=moderate; Gr 3=severe; Gr 4=potentially life-threatening. Neutrophils (absolute) (adult and infants \>7 days): Gr 1=1.000-1300/mm\^3; Gr 2=750-999 mm\^3; Gr 3=500-749 mm\^3; Gr 4= \<500 mm\^3. Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase: Gr 1=1.25-2.5\*upper limit of normal (ULN); Gr 2=2.6-5.0\*ULN; Gr 3=5.1-10.0\*ULN; Gr 4= \>10.0\*ULN. Bilirubin, total (adults and infants \>14 days): Gr 1=1.1-1.5\*ULN; Gr 2=1.6-2.5\*ULN; Gr 3=2.6-5.0\*ULN; Gr 4= \>5.0\*ULN. Lipase: Gr 1=1.1-1.5\*ULN; Gr 2=1.6-3.0\*ULN; Gr 3=3.1-5.0\*ULN; Gr 4= \>5.0\*ULN. Bicarbonate, serum low: Gr 1=16.0 mEq/L-\<lower limit of normal; Gr 2=11.0-15.9 mEq/L; Gr 3=8.0-10.9 mEq/L; Gr 4= \<8 mEq/L. By criteria of the World Health Organization: Amylase: Gr 1=1.0-1.39\*ULN; Gr 2=1.40-2.09\*ULN; Gr 3.=2.10-5.0\*ULN; Gr 4= \>5.0\*ULN.

Time frame:
Day one to week 300 (approximately 22-Jan-2018)
Reported as:
Number · Participants
Number of Participants With Laboratory Test Results Meeting the Criteria for Grade 3-4 Abnormality on ATV Powder
ParticipantsAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Neutrophils (absolute)00460
Alanine aminotransferase41120
Aspartate aminotransferase20100
Alkaline phosphatase12100
Total bilirubin411052
Amylase157661
Lipase32021
Bicarbonate20000
Albumin11010
Calcium, High00010
Chloride, Low00010
Total Cholesterol, Fasting00100
LDL Cholesterol, Fasting00100
Glucose, Fasting, Low00100
SecondaryNumber of Participants With HIV RNA <50 Copies/mL and <400 Copies/mL in the Week 24 Atazanavir Powder Cohort and the Eligible Week 48 Atazanavir Powder Cohort

Virologic success includes patients with HIV RNA \<50 copies/mL. Two cohorts were assessed: The Atazanavir Powder Cohort=patients who received treatment and did not switch to capsule before analysis Week 24 or before their HIV RNA Week 24 assessment, and the Eligible Week 48 Atazanavir Powder Cohort=patients who initiated study treatment at least 48 weeks before last person last visit and did not switch to capsule before analysis Week 48 or before their HIV RNA Week 48 assessment.

Time frame:
Day 1 of treatment to weeks 24 and 48
Reported as:
Number · Participants
Number of Participants With HIV RNA <50 Copies/mL and <400 Copies/mL in the Week 24 Atazanavir Powder Cohort and the Eligible Week 48 Atazanavir Powder Cohort
ParticipantsAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Week 24: HIV RNA<50 copies/mL10210195
Week 24: HIV RNA<400 copies/mL15515246
Week 48: HIV RNA<50 copies/mL1106181
Week 48:HIV RNA<400 copies/mL14114221
SecondaryMean Change From Baseline in HIV RNA on ATV Powder

Human immunodeficiency virus ribonucleic acid (HIV RNA) change from baseline using observed values

Time frame:
Baseline to Weeks 24 and 48
Reported as:
Mean · Log copies per millileter
Mean Change From Baseline in HIV RNA on ATV Powder
Log copies per millileterAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Week 24-2.10 ± 0.2863-3.07 ± 0.4780-2.69 ± 0.2257-2.66 ± 0.1550-2.24 ± 0.3821
Week 48-2.31 ± 0.3174-4.06 ± 0.1649-2.91 ± 0.1883-2.70 ± 0.1269-3.97 ± NA
SecondaryMean Change From Baseline in CD4 Percent on ATV Powder

Change in CD4 percent using observed values

Time frame:
Baseline to Weeks 24 and 48
Reported as:
Mean · Percent Change
Mean Change From Baseline in CD4 Percent on ATV Powder
Percent ChangeAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Week 245.1 ± 1.5214.0 ± 1.5815.4 ± 2.4486.3 ± 1.280-0.3 ± 4.349
Week 482.8 ± 3.167—8.9 ± 2.1827.5 ± 1.8251.0 ± NA
SecondaryCD4 Cell Count Changes From Baseline on ATV Powder

CD4 cell count change from baseline using observed values

Time frame:
Baseline to Weeks 24 and 48
Reported as:
Mean · Cells/mm^3
CD4 Cell Count Changes From Baseline on ATV Powder
Cells/mm^3Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Week 24218.7 ± 259.10267.8 ± 425.659247.1 ± 110.739246.1 ± 72.044145.8 ± 78.443
Week 48-409.8 ± 437.686—400.0 ± 156.021335.4 ± 108.925213.0 ± NA
SecondaryNumber of Participants With Emergent Genotypic Substitutions on ATV Powder Through Week 48

Newly emergent substitutions are on-treatment substitutions that were not detected at baseline.Viral rebound in the resistance analysis was defined as: Less than a 1 log10 drop from baseline in plasma HIV RNA level by Week 16, confirmed by a second plasma HIV RNA level redrawn within 2 and 4 weeks from original sample. Or, a plasma HIV RNA level \>200 c/mL after Week 24, confirmed by a second plasma HIV RNA level redrawn within 2 and 4 weeks from original sample. Or, repeated plasma HIV RNA level ≥50 c/mL after Week 48. Viral rebound was defined as a plasma HIV RNA level ≥400 c/mL at any time in a patient who had previously achieved a plasma HIV RNA level \<50 c/mL. Or, a plasma HIV RNA level ≥50 c/mL and \<1,000 c/mL followed by a return to virologic suppression was considered a viral blip and not a viral rebound. NRTI=nucleoside reverse transcriptase inhibitor

Time frame:
Baseline through Week 48
Reported as:
Number · Participants
Number of Participants With Emergent Genotypic Substitutions on ATV Powder Through Week 48
ParticipantsAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Any PI substitutions40430
Any IAS-USA PI substitutions10200
Any select RT substitutions21210
NRTI11210
SecondaryMaximum Observed Plasma Concentration (Cmax)

To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV Cmax

Time frame:
Baseline to Week 2
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Maximum Observed Plasma Concentration (Cmax)5776.70 ± 3417.2085644.12 ± 3093.5164893.75 ± 2523.959
SecondaryMinimum Plasma Concentration (Cmin)

To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV Cmin

Time frame:
Baseline to Week 2
Reported as:
Mean · ng/mL
Minimum Plasma Concentration (Cmin)
ng/mLAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Minimum Plasma Concentration (Cmin)718.90 ± 432.747857.06 ± 599.2211030.64 ± 1070.932
SecondaryArea Under the Concentration-Time Curve [AUC(TAU)]

To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV AUC

Time frame:
Baseline to Week 2
Reported as:
Mean · ng.h./mL
Area Under the Concentration-Time Curve [AUC(TAU)]
ng.h./mLAtazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)
Area Under the Concentration-Time Curve [AUC(TAU)]49387.12 ± 26890.78259671.80 ± 31706.65556356.00 ± 35233.024

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B/L Weight 5 to lt 10kg (ATV 150mg)0/23 (0%)6/23 (26.1%)22/23 (95.7%)
B/L Weight 5 to lt 10kg (ATV 200mg)0/12 (0%)3/12 (25%)10/12 (83.3%)
B/L Weight 10 to lt 15kg0/21 (0%)8/21 (38.1%)19/21 (90.5%)
B/L Weight 15 to lt 25kg0/35 (0%)10/35 (28.6%)31/35 (88.6%)
B/L Weight 25 to lt 35kg0/8 (0%)0/8 (0%)7/8 (87.5%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventB/L Weight 5 to lt 10kg (ATV 150mg)B/L Weight 5 to lt 10kg (ATV 200mg)B/L Weight 10 to lt 15kgB/L Weight 15 to lt 25kgB/L Weight 25 to lt 35kg
GastroenteritisInfections and infestations1/231/121/210/350/8
PertussisInfections and infestations0/231/120/210/350/8
Pulmonary tuberculosisInfections and infestations0/231/120/210/350/8
Pneumonitis chemicalInjury, poisoning and procedural complications0/231/120/210/350/8
OverdoseInjury, poisoning and procedural complications0/230/120/212/350/8
Alanine aminotransferase increasedInvestigations0/230/121/212/350/8
LymphadenopathyBlood and lymphatic system disorders0/230/121/210/350/8
VomitingGastrointestinal disorders0/230/121/210/350/8
DysenteryInfections and infestations1/230/121/210/350/8
Infective corneal ulcerInfections and infestations0/230/121/210/350/8
Most frequent other events
Showing 10 of 107
Most frequent other events
EventB/L Weight 5 to lt 10kg (ATV 150mg)B/L Weight 5 to lt 10kg (ATV 200mg)B/L Weight 10 to lt 15kgB/L Weight 15 to lt 25kgB/L Weight 25 to lt 35kg
Upper respiratory tract infectionInfections and infestations16/235/125/2110/352/8
GastroenteritisInfections and infestations14/233/1211/218/352/8
Lower respiratory tract infectionInfections and infestations7/235/121/211/351/8
Oral candidiasisInfections and infestations9/234/121/210/350/8
PyrexiaGeneral disorders3/230/128/214/353/8
NasopharyngitisInfections and infestations2/230/128/216/350/8
VomitingGastrointestinal disorders7/231/126/219/353/8
AnaemiaBlood and lymphatic system disorders8/232/120/212/350/8
Candida nappy rashInfections and infestations8/232/121/210/350/8
Nasal congestionRespiratory, thoracic and mediastinal disorders5/234/120/214/350/8

Baseline characteristics

All participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(Months)Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)Total
Mean8.4 ± 6.4210.5 ± 9.2137.4 ± 12.4467.2 ± 16.7093.4 ± 15.5342.5 ± 31.58
Sex: Female, Male
Sex: Female, Male(Participants)Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)Total
Female1261218351
Male116917548
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)Total
Hispanic or Latino012104
Not Hispanic or Latino111104
Unknown or Not Reported22101833891
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)Total
White221213332
Black/African American196720557
Other2422010
Region of Enrollment
Region of Enrollment(Participants)Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)Total
North America2194218
South America111418
Africa2010821564
Europe003609
Country
Country(Participants)Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg)Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg)Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg)Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg)Total
Argentina011204
Brazil000101
Chile100113
Mexico1174215
Poland001001
Romania000101
Russia001304
South Africa2010821564
Spain001203
United States102003
08

Study locations

32 sites
  • Children'S National Medical Center
    Washington, District of Columbia 20010, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Local Institution
    Buenos Aires, Bs As, Buenos Aires 1141, Argentina
  • Local Institution
    Bunos Aires, Buenos Aires 1425, Argentina
  • Local Institution
    Recife, Pernambuco 50070-500, Brazil
  • Local Institution
    Porto Alegre, RIO Grande DO SUL 90020-090, Brazil
  • Local Institution
    Porto Alegre, RIO Grande DO SUL 90035-903, Brazil
  • Local Institution
    Ribeirao Preto, SAO Paulo 14049-900, Brazil
  • Local Institution
    Santiago, Metropolitana 8380418, Chile
  • Local Institution
    Santiago, Metropolitana, Chile
  • Local Institution
    Df, Distrito Federal 06720, Mexico
  • Local Institution
    Guadalajara, Jalisco 44160, Mexico
  • Local Institution
    Guadalajara, Jalisco 44280, Mexico
  • Local Institution
    Merida, Yucatan 97000, Mexico
  • Local Institution
    Oaxaca, 71256, Mexico
  • Local Institution
    Puebla, 72000, Mexico
  • Local Institution
    Warszawa, 01-201, Poland
  • Local Institution
    Bucharest, 72205, Romania
  • Local Institution
    Smolensk, 214006, Russian Federation
  • Local Institution
    St. Petersburg, 189635, Russian Federation
  • Local Institution
    St.petersburg, 198103, Russian Federation
  • Local Institution
    Port Elizabeth, Eastern CAPE 6001, South Africa
  • Local Institution
    Port Elizabeth, Eastern CAPE 6014, South Africa
  • Local Institution
    Bloemfontein, FREE State 9301, South Africa
  • Local Institution
    Benoni, Gauteng 1501, South Africa
  • Local Institution
    Coronationville, Gauteng 2092, South Africa
  • Local Institution
    Pretoria, Gauteng 0001, South Africa
  • Local Institution
    Soweto, Gauteng 2001, South Africa
  • Local Institution
    Parrow Valley, Western CAPE 7505, South Africa
  • Local Institution
    Barcelona, 08950, Spain
  • Local Institution
    Madrid, 28041, Spain
  • Local Institution
    Birmingham, WEST Midlands B9 5ST, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2011 to primary completion in Sep 2014, 39 months.

Results were first posted in Feb 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2011
First posted
Apr 14, 2011
StartActual
May 27, 2011
Primary completionActual
Sep 10, 2014
CompletionActual
Jan 22, 2018
Results first posted
Feb 8, 2016
Last update
Nov 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01335698
Responsible party
Sponsor
First posted
Apr 14, 2011
Start date
May 27, 2011
Primary completion
Sep 10, 2014
Completion
Jan 22, 2018
Results posted
Feb 8, 2016
Last update
Nov 9, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ritonavir

Start the discussion